In the 2026 China PIII, Innovent Biologics ranked 4th in both Innovation and Invention, demonstrating its overall competitiveness in innovative drug R&D, commercialization and global development. In 2025, the company's product revenue exceeded RMB 10 billion, and it achieved full-year profitability for the first time; multiple differentiated innovative drugs were approved, and key pipeline programs advanced into global registrational clinical development. As its "dual-engine" strategy of oncology and general biomedicine continues to deepen, Innovent is consolidating its strengths in oncology while accelerating expansion into metabolic, autoimmune and ophthalmic diseases, and advancing the international development and value realization of its proprietary innovative assets through global strategic partnerships.

Innovent's innovative drug commercialization continued to scale up in 2025, with rapid product revenue growth and its first fullyear profit together reflecting enhanced operational capabilities...

Download the report to see the full company profile.